CNBC has highlighted Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine six-month implant of buprenorphine in a feature about the treatment of opioid addiction and the crisis of fatal overdoses in the U.S.
The feature discusses the potential benefits of an implant, compared with current sublingual versions of buprenorphine, and the relatively low percentage of doctors authorized to write prescriptions for buprenorphine.
The FDA is expected to rule by the end of this month on whether Titan’s Probuphine can go on sale. The product has been licensed to Braeburn Pharmaceuticals.
The CNBC feature can be accessed here.